Chicago, United States
Nucleai is a healthcare startup founded in 2017 and headquartered in the United States. The company's slogan, "The leading Spatial Biology Software Platform for Precision Medicine," exemplifies their focus on leveraging AI-powered spatial biology technology to advance precision medicine.
Nucleai's efforts are aimed at enhancing drug development, improving clinical treatment decisions, and ultimately, enhancing patient outcomes. Their flagship product, Atom, is heralded as the premier spatial biology platform for precision medicine.
Notably, the company has secured a significant $14.00M Venture Round investment, with the MERL Ventures Fund participating in this latest round in 03 April 2024. Nucleai has also established partnerships with leading pharmaceutical companies, with collaborations on biomarker discovery projects and the licensing of their research platform for internal use.
Through these endeavors, Nucleai is positioning itself as a key player in advancing precision medicine, with strong backing from prominent investors and a clear focus on addressing critical needs in the healthcare industry.
